Elevation of conjunctival epithelial CD45INTCD11b+CD16+CD14- neutrophils in ocular Stevens-Johnson syndrome and toxic epidermal necrolysis

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 7, 2013, Pages 4578-4585

  Williams, Geraint P ^a,b   Tomlins, Paul J ^a,b   Denniston, Alastair K ^a,b   Southworth, H Susan ^a,b   Sreekantham, Sreekanth ^a,b   Curnow, S John ^a,b   Rauz, Saaeha ^a,b  

^a CITY HOSPITAL   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Innate immunity; Neutrophils; SJS; TEN

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; CD45 ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONJUNCTIVA DISEASE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FOLLOW UP; HUMAN; LIMIT OF QUANTITATION; MALE; NEUTROPHIL; PRIORITY JOURNAL; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

INNATE IMMUNITY; NEUTROPHILS; SJS; TEN;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIGENS, CD; CHRONIC DISEASE; CONJUNCTIVA; CONJUNCTIVAL DISEASES; CROSS-SECTIONAL STUDIES; EPIDERMAL NECROLYSIS, TOXIC; EPITHELIUM; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; NEUTROPHILS; STEVENS-JOHNSON SYNDROME; YOUNG ADULT;

EID: 84880068168     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-11859     Document Type: Article

References (38)

1. Wojnarowska FT, Briggaman RA. Management of Blistering Diseases. London: Chapman and Hall Medical; 1990.
2. Saw VP, Dart JK. Ocular mucous membrane pemphigoid: diagnosis and management strategies. Ocul Surf. 2008;6:128-142.
3. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149-153.
4. Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol. 1991;127:839-842.
5. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92-96.
6. Foster CS, Fong LP, Azar D, Kenyon KR. Episodic conjunctival inflammation after Stevens-Johnson syndrome. Ophthalmology. 1988;95:453-462.
7. De Rojas MV, Dart JK, Saw VP. The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol. 2007;91:1048-1053.
8. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14:1343-1350.
9. Williams GP, Mudhar HS, Leyland M. Early pathological features of the cornea in toxic epidermal necrolysis. Br J Ophthalmol. 2007;91:1129-1132.
10. Ueta M, Sotozono C, Inatomi T, et al. Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens-Johnson syndrome. Br J Ophthalmol. 2007;91:962-965.
11. Brignole-Baudouin F, Ott AC, Warnet JM, Baudouin C. Flow cytometry in conjunctival impression cytology: a new tool for exploring ocular surface pathologies. Exp Eye Res. 2004;78: 473-481.
12. Williams GP, Denniston AK, Oswal KS, et al. The dominant human conjunctival epithelial CD8alphabeta{thorn} T cell population is maintained with age but the number of CD4{thorn} T cells increases. Age (Dordr). 2012;34:1517-1528.
13. Sotozono C, Ang LP, Koizumi N, et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. Ophthalmology. 2007;114: 1294-1302.
14. Elder MJ, Bernauer, W. Monitoring of activity and progression in cicatrising conjunctivitis. In: Bernauer W, Dart JKG, Elder MJ, eds. Cicatrising Conjunctivitis. Basel, Switzerland: Karger; 1997:111-122.
15. Power WJ, Ghoraishi M, Merayo-Lloves J, Neves RA, Foster CS. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology. 1995;102: 1669-1676.
16. Williams GP, Saw VP, Saeed T, et al. Validation of a fornix depth measurer: a putative tool for the assessment of progressive cicatrising conjunctivitis. Br J Ophthalmol. 2011;95:842-847.
17. Stelzer GT, Shults KE, Loken MR. CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann N Y Acad Sci. 1993;677:265-280.
18. Gopinath R, Nutman TB. Identification of eosinophils in lysed whole blood using side scatter and CD16 negativity. Cytometry. 1997;30:313-316.
19. Ziegler-Heitbrock L. The CD14{thorn} CD16{thorn} blood monocytes: their role in infection and inflammation. J Leukoc Biol. 2007; 81:584-592.
20. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1607.
21. French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int. 2006;55:9-16.
22. Chan LS, Soong HK, Foster CS, Hammerberg C, Cooper KD. Ocular cicatricial pemphigoid occurring as a sequela of Stevens-Johnson syndrome. JAMA. 1991;266:1543-1546.
23. Ueta M, Kinoshita S. Ocular surface inflammation mediated by innate immunity. Eye Contact Lens. 2010;36:269-281.
24. Baudouin C, Brignole F, Pisella PJ, De Jean MS, Goguel A. Flow cytometric analysis of the inflammatory marker HLA DR in dry eye syndrome: results from 12 months of randomized treatment with topical cyclosporin A. Adv Exp Med Biol. 2002;506:761-769.
25. Hingorani M, Metz D, Lightman SL. Characterisation of the normal conjunctival leukocyte population. Exp Eye Res. 1997; 64:905-912.
26. Quinn AM, Brown K, Bonish BK, et al. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol. 2005;141:683-687.
27. Tohyama M, Watanabe H, Murakami S, et al. Possible involvement of CD14{thorn} CD16{thorn} monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2012;166:322-330.
28. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol. 2006;6:173-182.
29. Sonawane S, Khanolkar V, Namavari A, et al. Ocular surface extracellular DNA and nuclease activity imbalance: a new paradigm for inflammation in dry eye disease. Invest Ophthalmol Vis Sci. 2012;53:8253-8263.
30. Stern ME, Gao J, Schwalb TA, et al. Conjunctival T-cell subpopulations in Sjogren's and non-Sjogren's patients with dry eye. Invest Ophthalmol Vis Sci. 2002;43:2609-2614.
31. Niederkorn JY, Stern ME, Pflugfelder SC, et al. Desiccating stress induces T cell-mediated Sj̈ogren's Syndrome-like lacrimal keratoconjunctivitis. J Immunol. 2006;176:3950-3957.
32. Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P, Halbwachs-Mecarelli L. Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest. 2000;80:617-653.
33. Chua F, Dunsmore SE, Clingen PH, et al. Mice lacking neutrophil elastase are resistant to bleomycin-induced pulmonary fibrosis. Am J Pathol. 2007;170:65-74.
34. Ueta M, Sotozono C, Yokoi N, Inatomi T, Kinoshita S. Prostaglandin E receptor subtype EP3 expression in human conjunctival epithelium and its changes in various ocular surface disorders. PLoS One. 2011;6:e25209.
35. Ueta M, Sotozono C, Yamada K, Yokoi N, Inatomi T, Kinoshita S. Expression of prostaglandin E receptor subtype EP4 in conjunctival epithelium of patients with ocular surface disorders: case-control study. BMJ Open. 2012;2: e001330.
36. Ueta M. Innate immunity of the ocular surface and ocular surface inflammatory disorders. Cornea. 2008;27(suppl 1): S31-S40.
37. Lopez-Garcia JS, Rivas Jara L, Garcia-Lozano CI, Conesa E, de Juan IE, Murube del Castillo J. Ocular features and histopathologic changes during follow-up of toxic epidermal necrolysis. Ophthalmology. 2011;118:265-271.
38. Barabino S, Montaldo E, Solignani F, Valente C, Mingari MC, Rolando M. Immune response in the conjunctival epithelium of patients with dry eye. Exp Eye Res. 2010;91:524-529.